MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer

Purpose: The process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting from the vasculature to seed and colonize distant tissues. miR-200a is involved in this multistep metastatic cascade. This study aimed to test t...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 19; no. 6; pp. 1389 - 1399
Main Authors Yu, San-Jian, Hu, Jing-Ying, Kuang, Xia-Ying, Luo, Jian-Min, Hou, Yi-Feng, Di, Gen-Hong, Wu, Jiong, Shen, Zhen-Zhou, Song, Hou-Yan, Shao, Zhi-Ming
Format Journal Article
LanguageEnglish
Published United States 15.03.2013
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Purpose: The process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting from the vasculature to seed and colonize distant tissues. miR-200a is involved in this multistep metastatic cascade. This study aimed to test the hypothesis that miR-200a promotes metastasis through increased anoikis resistance in breast cancer. Experimental Design: Breast cancer cells transfected with mimic or inhibitor for miR-200a were assayed for anoikis in vitro. miR-200a expression was assessed by quantitative real-time PCR (qRT-PCR). Luciferase assays, colony formation assays, and animal studies were conducted to identify the targets of miR-200a and the mechanism by which it promotes anoikis resistance. Results: We found that overexpression of miR-200a promotes whereas inhibition of miR-200a suppresses anoikis resistance in breast cancer cells. We identified Yes-associated protein 1 (YAP1) as a novel target of miR-200a. Our data showed that targeting of YAP1 by miR-200a resulted in decreased expression of proapoptotic proteins, which leads to anoikis resistance. Overexpression of miR-200a protected tumor cells from anoikis and promoted metastases in vivo. Furthermore, knockdown of YAP1 phenocopied the effects of miR-200a overexpression, whereas restoration of YAP1 in miR-200a overexpressed breast cancer cells reversed the effects of miR-200a on anoikis and metastasis. Remarkably, we found that YAP1 expression was inversely correlated with miR-200a expression in breast cancer clinical specimens, and miR-200a expression was associated with distant metastasis in patients with breast cancer. Conclusions: Our data suggest that miR-200a functions as anoikis suppressor and contributes to metastasis in breast cancer. Clin Cancer Res; 19(6); 1389–99. ©2013 AACR.
AbstractList Purpose: The process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting from the vasculature to seed and colonize distant tissues. miR-200a is involved in this multistep metastatic cascade. This study aimed to test the hypothesis that miR-200a promotes metastasis through increased anoikis resistance in breast cancer. Experimental Design: Breast cancer cells transfected with mimic or inhibitor for miR-200a were assayed for anoikis in vitro. miR-200a expression was assessed by quantitative real-time PCR (qRT-PCR). Luciferase assays, colony formation assays, and animal studies were conducted to identify the targets of miR-200a and the mechanism by which it promotes anoikis resistance. Results: We found that overexpression of miR-200a promotes whereas inhibition of miR-200a suppresses anoikis resistance in breast cancer cells. We identified Yes-associated protein 1 (YAP1) as a novel target of miR-200a. Our data showed that targeting of YAP1 by miR-200a resulted in decreased expression of proapoptotic proteins, which leads to anoikis resistance. Overexpression of miR-200a protected tumor cells from anoikis and promoted metastases in vivo. Furthermore, knockdown of YAP1 phenocopied the effects of miR-200a overexpression, whereas restoration of YAP1 in miR-200a overexpressed breast cancer cells reversed the effects of miR-200a on anoikis and metastasis. Remarkably, we found that YAP1 expression was inversely correlated with miR-200a expression in breast cancer clinical specimens, and miR-200a expression was associated with distant metastasis in patients with breast cancer. Conclusions: Our data suggest that miR-200a functions as anoikis suppressor and contributes to metastasis in breast cancer. Clin Cancer Res; 19(6); 1389–99. ©2013 AACR.
The process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting from the vasculature to seed and colonize distant tissues. miR-200a is involved in this multistep metastatic cascade. This study aimed to test the hypothesis that miR-200a promotes metastasis through increased anoikis resistance in breast cancer.PURPOSEThe process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting from the vasculature to seed and colonize distant tissues. miR-200a is involved in this multistep metastatic cascade. This study aimed to test the hypothesis that miR-200a promotes metastasis through increased anoikis resistance in breast cancer.Breast cancer cells transfected with mimic or inhibitor for miR-200a were assayed for anoikis in vitro. miR-200a expression was assessed by quantitative real-time PCR (qRT-PCR). Luciferase assays, colony formation assays, and animal studies were conducted to identify the targets of miR-200a and the mechanism by which it promotes anoikis resistance.EXPERIMENTAL DESIGNBreast cancer cells transfected with mimic or inhibitor for miR-200a were assayed for anoikis in vitro. miR-200a expression was assessed by quantitative real-time PCR (qRT-PCR). Luciferase assays, colony formation assays, and animal studies were conducted to identify the targets of miR-200a and the mechanism by which it promotes anoikis resistance.We found that overexpression of miR-200a promotes whereas inhibition of miR-200a suppresses anoikis resistance in breast cancer cells. We identified Yes-associated protein 1 (YAP1) as a novel target of miR-200a. Our data showed that targeting of YAP1 by miR-200a resulted in decreased expression of proapoptotic proteins, which leads to anoikis resistance. Overexpression of miR-200a protected tumor cells from anoikis and promoted metastases in vivo. Furthermore, knockdown of YAP1 phenocopied the effects of miR-200a overexpression, whereas restoration of YAP1 in miR-200a overexpressed breast cancer cells reversed the effects of miR-200a on anoikis and metastasis. Remarkably, we found that YAP1 expression was inversely correlated with miR-200a expression in breast cancer clinical specimens, and miR-200a expression was associated with distant metastasis in patients with breast cancer.RESULTSWe found that overexpression of miR-200a promotes whereas inhibition of miR-200a suppresses anoikis resistance in breast cancer cells. We identified Yes-associated protein 1 (YAP1) as a novel target of miR-200a. Our data showed that targeting of YAP1 by miR-200a resulted in decreased expression of proapoptotic proteins, which leads to anoikis resistance. Overexpression of miR-200a protected tumor cells from anoikis and promoted metastases in vivo. Furthermore, knockdown of YAP1 phenocopied the effects of miR-200a overexpression, whereas restoration of YAP1 in miR-200a overexpressed breast cancer cells reversed the effects of miR-200a on anoikis and metastasis. Remarkably, we found that YAP1 expression was inversely correlated with miR-200a expression in breast cancer clinical specimens, and miR-200a expression was associated with distant metastasis in patients with breast cancer.Our data suggest that miR-200a functions as anoikis suppressor and contributes to metastasis in breast cancer.CONCLUSIONSOur data suggest that miR-200a functions as anoikis suppressor and contributes to metastasis in breast cancer.
The process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting from the vasculature to seed and colonize distant tissues. miR-200a is involved in this multistep metastatic cascade. This study aimed to test the hypothesis that miR-200a promotes metastasis through increased anoikis resistance in breast cancer. Breast cancer cells transfected with mimic or inhibitor for miR-200a were assayed for anoikis in vitro. miR-200a expression was assessed by quantitative real-time PCR (qRT-PCR). Luciferase assays, colony formation assays, and animal studies were conducted to identify the targets of miR-200a and the mechanism by which it promotes anoikis resistance. We found that overexpression of miR-200a promotes whereas inhibition of miR-200a suppresses anoikis resistance in breast cancer cells. We identified Yes-associated protein 1 (YAP1) as a novel target of miR-200a. Our data showed that targeting of YAP1 by miR-200a resulted in decreased expression of proapoptotic proteins, which leads to anoikis resistance. Overexpression of miR-200a protected tumor cells from anoikis and promoted metastases in vivo. Furthermore, knockdown of YAP1 phenocopied the effects of miR-200a overexpression, whereas restoration of YAP1 in miR-200a overexpressed breast cancer cells reversed the effects of miR-200a on anoikis and metastasis. Remarkably, we found that YAP1 expression was inversely correlated with miR-200a expression in breast cancer clinical specimens, and miR-200a expression was associated with distant metastasis in patients with breast cancer. Our data suggest that miR-200a functions as anoikis suppressor and contributes to metastasis in breast cancer.
Author Shen, Zhen-Zhou
Hu, Jing-Ying
Song, Hou-Yan
Di, Gen-Hong
Luo, Jian-Min
Shao, Zhi-Ming
Kuang, Xia-Ying
Wu, Jiong
Yu, San-Jian
Hou, Yi-Feng
Author_xml – sequence: 1
  givenname: San-Jian
  surname: Yu
  fullname: Yu, San-Jian
– sequence: 2
  givenname: Jing-Ying
  surname: Hu
  fullname: Hu, Jing-Ying
– sequence: 3
  givenname: Xia-Ying
  surname: Kuang
  fullname: Kuang, Xia-Ying
– sequence: 4
  givenname: Jian-Min
  surname: Luo
  fullname: Luo, Jian-Min
– sequence: 5
  givenname: Yi-Feng
  surname: Hou
  fullname: Hou, Yi-Feng
– sequence: 6
  givenname: Gen-Hong
  surname: Di
  fullname: Di, Gen-Hong
– sequence: 7
  givenname: Jiong
  surname: Wu
  fullname: Wu, Jiong
– sequence: 8
  givenname: Zhen-Zhou
  surname: Shen
  fullname: Shen, Zhen-Zhou
– sequence: 9
  givenname: Hou-Yan
  surname: Song
  fullname: Song, Hou-Yan
– sequence: 10
  givenname: Zhi-Ming
  surname: Shao
  fullname: Shao, Zhi-Ming
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23340296$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtPxCAUhYnROI76EzQs3XQECqWNq9r4SnxlMi5cEUrpBG2pAl3476WZmY0LV1xuvnNv7jlzsG8HqwE4w2iBMcsvMeJ5gmhKFlW1TDBJcMGKPXCEGeNJSjK2H-sdMwNz7z8QwhQjeghmJE0pIkV2BOSTUW5YPpcJQUjCVzf0Q9AelnYwn8bDpfbGB2mVhtI28EkHGb-xB-sfuJJurYOxa_hevmJoLLwfe2nhtdORgtUkcyfgoJWd16fb9xi83d6sqvvk8eXuoSofE5VyFhKeZYjUDCvect5KRZsm10qqTKmsqTnNOMsp12lLdUuKppCE1Vw2Kp7HMp7z9BhcbOZ-ueF71D6I3nilu05aPYxe4BTznCFEcUTPt-hY97oRX8700v2InS0RuNoA0RvvnW6FMkEGM9jgpOkERmIKQUwGi8lgEUMQmIgphKhmf9S7Bf_rfgE5m4kg
CitedBy_id crossref_primary_10_18632_oncotarget_20155
crossref_primary_10_1016_j_canlet_2017_04_011
crossref_primary_10_1016_j_canlet_2014_08_036
crossref_primary_10_1371_journal_pone_0309289
crossref_primary_10_2174_1574892814666181231142136
crossref_primary_10_3892_etm_2018_6895
crossref_primary_10_1038_s41598_024_73632_0
crossref_primary_10_18632_oncotarget_16577
crossref_primary_10_18632_oncotarget_21913
crossref_primary_10_1016_j_celrep_2018_10_001
crossref_primary_10_1111_cpr_12527
crossref_primary_10_3389_fgene_2023_1134779
crossref_primary_10_1002_jcp_29040
crossref_primary_10_1016_j_bbamcr_2013_06_026
crossref_primary_10_1007_s00404_022_06442_2
crossref_primary_10_1016_j_lfs_2020_118303
crossref_primary_10_1016_j_pharmthera_2017_12_011
crossref_primary_10_3892_or_2017_5600
crossref_primary_10_1016_j_ccell_2014_11_025
crossref_primary_10_1038_nrc3789
crossref_primary_10_1038_emm_2017_33
crossref_primary_10_1016_j_canlet_2017_04_032
crossref_primary_10_1016_j_jacbts_2024_02_019
crossref_primary_10_3390_cancers13236020
crossref_primary_10_1248_bpb_b19_00795
crossref_primary_10_1038_s41418_017_0012_4
crossref_primary_10_1186_s12935_021_01999_5
crossref_primary_10_1038_s41388_020_1166_y
crossref_primary_10_3390_genes14051075
crossref_primary_10_3390_cancers12051225
crossref_primary_10_4048_jbc_2019_22_e19
crossref_primary_10_1134_S1022795418070086
crossref_primary_10_1177_00220345241242047
crossref_primary_10_3892_ol_2013_1593
crossref_primary_10_1016_j_lfs_2023_121980
crossref_primary_10_1007_s11010_024_05199_3
crossref_primary_10_1016_j_jhep_2015_01_039
crossref_primary_10_1016_j_humpath_2017_08_032
crossref_primary_10_18632_oncotarget_3052
crossref_primary_10_7717_peerj_10397
crossref_primary_10_1016_j_prp_2018_04_010
crossref_primary_10_1186_1476_4598_13_256
crossref_primary_10_1002_mco2_718
crossref_primary_10_1007_s11033_021_06666_6
crossref_primary_10_3390_cancers10040115
crossref_primary_10_1038_s41598_021_82431_w
crossref_primary_10_1038_s41598_023_51124_x
crossref_primary_10_1186_s12885_022_10118_0
crossref_primary_10_3390_cancers14205121
crossref_primary_10_1016_j_biopha_2017_06_055
crossref_primary_10_1007_s11010_022_04384_6
crossref_primary_10_1016_j_bbcan_2014_02_002
crossref_primary_10_3390_biom12060781
crossref_primary_10_1038_s41388_021_02000_3
crossref_primary_10_4251_wjgo_v15_i6_988
crossref_primary_10_3389_fonc_2018_00580
crossref_primary_10_1002_gcc_22422
crossref_primary_10_1038_s41598_021_89855_4
crossref_primary_10_1038_s41598_021_89288_z
crossref_primary_10_1007_s13277_014_2202_8
crossref_primary_10_1016_j_prp_2021_153405
crossref_primary_10_1186_s12885_017_3930_0
crossref_primary_10_1371_journal_pone_0135119
crossref_primary_10_1172_JCI75695
crossref_primary_10_1016_j_ygyno_2014_01_047
crossref_primary_10_1002_cbf_3119
crossref_primary_10_3892_or_2015_4168
crossref_primary_10_3390_cancers13123100
crossref_primary_10_1177_1533033819828709
crossref_primary_10_2217_fon_2020_1080
crossref_primary_10_1007_s12094_015_1353_4
crossref_primary_10_1017_erm_2015_12
crossref_primary_10_3389_fonc_2021_708765
crossref_primary_10_1016_j_hjc_2020_10_006
crossref_primary_10_1074_jbc_RA118_004251
crossref_primary_10_3389_fonc_2023_1226118
crossref_primary_10_1002_adbi_202300532
crossref_primary_10_1007_s11596_018_1872_7
crossref_primary_10_1021_acs_biochem_5b01014
crossref_primary_10_1007_s12282_025_01666_x
crossref_primary_10_1016_j_drup_2024_101099
crossref_primary_10_3389_fphar_2016_00271
crossref_primary_10_1186_s12935_021_02408_7
crossref_primary_10_1080_2162402X_2016_1160187
crossref_primary_10_1111_jog_13027
crossref_primary_10_1155_2018_4039173
crossref_primary_10_1080_10641955_2020_1757700
crossref_primary_10_1093_carcin_bgu202
crossref_primary_10_1038_s41598_021_82286_1
crossref_primary_10_1016_j_mam_2019_09_005
crossref_primary_10_1186_s13046_016_0338_7
crossref_primary_10_1016_j_ejca_2016_11_004
crossref_primary_10_3390_biology10040307
crossref_primary_10_4161_rna_26541
crossref_primary_10_3390_cells9081790
crossref_primary_10_1007_s12094_015_1364_1
crossref_primary_10_3390_ijms23179535
crossref_primary_10_1016_j_canlet_2024_216672
crossref_primary_10_1155_2018_2754941
crossref_primary_10_1016_j_isci_2024_110638
crossref_primary_10_1371_journal_pone_0159686
crossref_primary_10_3748_wjg_v21_i11_3245
crossref_primary_10_1016_j_canlet_2021_04_025
crossref_primary_10_1016_j_critrevonc_2015_12_004
crossref_primary_10_1161_ATVBAHA_115_305748
crossref_primary_10_1007_s11010_022_04353_z
crossref_primary_10_1159_000507538
crossref_primary_10_3390_cancers14143386
crossref_primary_10_1007_s10555_013_9463_3
crossref_primary_10_1186_s12964_023_01183_4
crossref_primary_10_3390_pharmaceutics12121193
crossref_primary_10_1038_srep11567
crossref_primary_10_1016_j_cellsig_2019_109460
crossref_primary_10_1016_j_yexcr_2018_04_024
crossref_primary_10_1371_journal_pone_0206644
crossref_primary_10_3389_fgene_2019_00180
Cites_doi 10.1016/j.molcel.2010.05.018
10.1038/nprot.2010.150
10.1158/0008-5472.CAN-05-1150
10.1016/j.bcp.2008.07.023
10.4161/cc.10.21.17921
10.1016/S1097-2765(02)00776-1
10.1093/nar/gkm995
10.1074/jbc.M010484200
10.1038/sj.cdd.4402063
10.1074/jbc.C800074200
10.1093/nar/gkr1048
10.1038/nm.2401
10.1016/j.canlet.2008.05.029
10.1155/2010/821717
10.1158/0008-5472.CAN-09-2111
10.1016/j.cell.2011.02.013
10.1038/ncb1722
10.1158/1078-0432.CCR-07-1731
10.1016/j.cell.2009.03.047
10.1016/j.molcel.2007.08.008
10.1038/nature06174
10.1038/nature06487
10.1016/j.cell.2009.07.011
10.1016/j.cell.2005.06.007
10.1074/jbc.M804380200
10.1016/j.molcel.2007.06.017
10.1158/0008-5472.CAN-08-1942
10.1016/j.molcel.2007.12.022
10.1038/nrc1670
10.1126/science.1203543
10.1101/gad.1640608
10.1056/NEJMoa050518
10.1016/j.molcel.2010.08.013
10.1038/cdd.2008.108
10.1016/S0140-6736(07)60781-8
10.1038/embor.2008.74
10.1371/journal.pone.0007181
10.1093/nar/gkp292
10.1371/journal.pbio.0020363
10.1093/bioinformatics/btq675
10.1016/j.ygyno.2009.05.022
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1158/1078-0432.CCR-12-1959
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1557-3265
EndPage 1399
ExternalDocumentID 23340296
10_1158_1078_0432_CCR_12_1959
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
18M
29B
2FS
2WC
34G
39C
53G
5GY
5RE
5VS
6J9
AAFWJ
AAJMC
AAYXX
ABOCM
ACGFO
ACIWK
ACPRK
ACSVP
ADBBV
ADCOW
ADNWM
AENEX
AFHIN
AFOSN
AFRAH
AFUMD
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BR6
BTFSW
CITATION
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
H13
IH2
KQ8
L7B
LSO
OK1
P0W
P2P
QTD
RCR
RHI
RNS
SJN
TR2
UDS
W2D
W8F
WOQ
YKV
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c375t-76602b51c7f77fac4dd8ecac6cc6db74675847e3f4ef29d9a25b7adc043567873
ISSN 1078-0432
1557-3265
IngestDate Thu Jul 10 19:02:20 EDT 2025
Thu Apr 03 07:01:44 EDT 2025
Thu Apr 24 23:09:21 EDT 2025
Tue Jul 01 03:06:42 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c375t-76602b51c7f77fac4dd8ecac6cc6db74675847e3f4ef29d9a25b7adc043567873
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 23340296
PQID 1317850041
PQPubID 23479
PageCount 11
ParticipantIDs proquest_miscellaneous_1317850041
pubmed_primary_23340296
crossref_citationtrail_10_1158_1078_0432_CCR_12_1959
crossref_primary_10_1158_1078_0432_CCR_12_1959
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-03-15
PublicationDateYYYYMMDD 2013-03-15
PublicationDate_xml – month: 03
  year: 2013
  text: 2013-03-15
  day: 15
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical cancer research
PublicationTitleAlternate Clin Cancer Res
PublicationYear 2013
References Basu (2022061106492973200_bib21) 2003; 11
Chaffer (2022061106492973200_bib14) 2011; 331
Dykxhoorn (2022061106492973200_bib15) 2009; 4
Matallanas (2022061106492973200_bib31) 2007; 27
Shimono (2022061106492973200_bib10) 2009; 138
John (2022061106492973200_bib25) 2004; 2
Hu (2022061106492973200_bib40) 2009; 114
Grimson (2022061106492973200_bib24) 2007; 27
Ma (2022061106492973200_bib4) 2007; 449
Yuan (2022061106492973200_bib18) 2008; 15
Strano (2022061106492973200_bib32) 2001; 276
Schickel (2022061106492973200_bib7) 2010; 38
Dimmer (2022061106492973200_bib28) 2012; 40
Levy (2022061106492973200_bib19) 2008; 29
Gregory (2022061106492973200_bib23) 2008; 10
Simpson (2022061106492973200_bib35) 2008; 272
Berry (2022061106492973200_bib1) 2005; 353
Park (2022061106492973200_bib12) 2008; 22
Weigelt (2022061106492973200_bib3) 2005; 5
Cochrane (2022061106492973200_bib8) 2010; 2010
Eguiara (2022061106492973200_bib33) 2011; 10
Korpal (2022061106492973200_bib16) 2011; 17
Hurst (2022061106492973200_bib17) 2009; 69
Smoot (2022061106492973200_bib29) 2011; 27
Iliopoulos (2022061106492973200_bib9) 2010; 39
Rouhi (2022061106492973200_bib22) 2010; 5
Betel (2022061106492973200_bib26) 2008; 36
Tavazoie (2022061106492973200_bib5) 2008; 451
Oka (2022061106492973200_bib37) 2008; 283
Nam (2022061106492973200_bib41) 2008; 14
Maragkakis (2022061106492973200_bib27) 2009; 37
Eccles (2022061106492973200_bib2) 2007; 369
Huang (2022061106492973200_bib20) 2005; 122
Bracken (2022061106492973200_bib11) 2008; 68
Aqeilan (2022061106492973200_bib38) 2005; 65
Korpal (2022061106492973200_bib13) 2008; 283
Valastyan (2022061106492973200_bib6) 2009; 137
Hanahan (2022061106492973200_bib36) 2011; 144
Levy (2022061106492973200_bib30) 2006; 14
Chiarugi (2022061106492973200_bib39) 2008; 76
Burk (2022061106492973200_bib34) 2008; 9
References_xml – volume: 38
  start-page: 908
  year: 2010
  ident: 2022061106492973200_bib7
  article-title: mir-200c regulates induction of apoptosis through CD95 by targeting FAP-1
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2010.05.018
– volume: 5
  start-page: 1911
  year: 2010
  ident: 2022061106492973200_bib22
  article-title: Hypoxia-induced metastasis model in embryonic zebrafish
  publication-title: Nat Protoc
  doi: 10.1038/nprot.2010.150
– volume: 65
  start-page: 6764
  year: 2005
  ident: 2022061106492973200_bib38
  article-title: WW domain–containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-1150
– volume: 76
  start-page: 1352
  year: 2008
  ident: 2022061106492973200_bib39
  article-title: Anoikis: a necessary death program for anchorage-dependent cells
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2008.07.023
– volume: 10
  start-page: 3751
  year: 2011
  ident: 2022061106492973200_bib33
  article-title: Xenografts in zebrafish embryos as a rapid functional assay for breast cancer stem-like cell identification
  publication-title: Cell Cycle
  doi: 10.4161/cc.10.21.17921
– volume: 11
  start-page: 11
  year: 2003
  ident: 2022061106492973200_bib21
  article-title: Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis
  publication-title: Mol Cell
  doi: 10.1016/S1097-2765(02)00776-1
– volume: 36
  start-page: D149
  year: 2008
  ident: 2022061106492973200_bib26
  article-title: The microRNA.org resource: targets and expression
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkm995
– volume: 276
  start-page: 15164
  year: 2001
  ident: 2022061106492973200_bib32
  article-title: Physical Interaction with Yes-associated protein enhances p73 transcriptional activity
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M010484200
– volume: 14
  start-page: 743
  year: 2006
  ident: 2022061106492973200_bib30
  article-title: The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73
  publication-title: Cell Death Differ
  doi: 10.1038/sj.cdd.4402063
– volume: 283
  start-page: 14910
  year: 2008
  ident: 2022061106492973200_bib13
  article-title: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2
  publication-title: J Biol Chem
  doi: 10.1074/jbc.C800074200
– volume: 40
  start-page: D565
  year: 2012
  ident: 2022061106492973200_bib28
  article-title: The UniProt-GO annotation database in 2011
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkr1048
– volume: 17
  start-page: 1101
  year: 2011
  ident: 2022061106492973200_bib16
  article-title: Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization
  publication-title: Nat Med
  doi: 10.1038/nm.2401
– volume: 272
  start-page: 177
  year: 2008
  ident: 2022061106492973200_bib35
  article-title: Anoikis resistance and tumor metastasis
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2008.05.029
– volume: 2010
  year: 2010
  ident: 2022061106492973200_bib8
  article-title: Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers
  publication-title: J Oncol
  doi: 10.1155/2010/821717
– volume: 69
  start-page: 7495
  year: 2009
  ident: 2022061106492973200_bib17
  article-title: Metastamir: the field of metastasis-regulatory microRNA Is spreading
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-09-2111
– volume: 144
  start-page: 646
  year: 2011
  ident: 2022061106492973200_bib36
  article-title: Hallmarks of cancer: The next generation
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 10
  start-page: 593
  year: 2008
  ident: 2022061106492973200_bib23
  article-title: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1722
– volume: 14
  start-page: 2690
  year: 2008
  ident: 2022061106492973200_bib41
  article-title: MicroRNA expression profiles in serous ovarian carcinoma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-1731
– volume: 137
  start-page: 1032
  year: 2009
  ident: 2022061106492973200_bib6
  article-title: A pleiotropically acting MicroRNA, miR-31, inhibits breast cancer metastasis
  publication-title: Cell
  doi: 10.1016/j.cell.2009.03.047
– volume: 27
  start-page: 962
  year: 2007
  ident: 2022061106492973200_bib31
  article-title: RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2007.08.008
– volume: 449
  start-page: 682
  year: 2007
  ident: 2022061106492973200_bib4
  article-title: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
  publication-title: Nature
  doi: 10.1038/nature06174
– volume: 451
  start-page: 147
  year: 2008
  ident: 2022061106492973200_bib5
  article-title: Endogenous human microRNAs that suppress breast cancer metastasis
  publication-title: Nature
  doi: 10.1038/nature06487
– volume: 138
  start-page: 592
  year: 2009
  ident: 2022061106492973200_bib10
  article-title: Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells
  publication-title: Cell
  doi: 10.1016/j.cell.2009.07.011
– volume: 122
  start-page: 421
  year: 2005
  ident: 2022061106492973200_bib20
  article-title: The hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating yorkie, the drosophila homolog of yap
  publication-title: Cell
  doi: 10.1016/j.cell.2005.06.007
– volume: 283
  start-page: 27534
  year: 2008
  ident: 2022061106492973200_bib37
  article-title: Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP)
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M804380200
– volume: 27
  start-page: 91
  year: 2007
  ident: 2022061106492973200_bib24
  article-title: MicroRNA targeting specificity in mammals: determinants beyond seed pairing
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2007.06.017
– volume: 68
  start-page: 7846
  year: 2008
  ident: 2022061106492973200_bib11
  article-title: A Double-Negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-1942
– volume: 29
  start-page: 350
  year: 2008
  ident: 2022061106492973200_bib19
  article-title: Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2007.12.022
– volume: 5
  start-page: 591
  year: 2005
  ident: 2022061106492973200_bib3
  article-title: Breast cancer metastasis: markers and models
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1670
– volume: 331
  start-page: 1559
  year: 2011
  ident: 2022061106492973200_bib14
  article-title: A perspective on cancer cell metastasis
  publication-title: Science
  doi: 10.1126/science.1203543
– volume: 22
  start-page: 894
  year: 2008
  ident: 2022061106492973200_bib12
  article-title: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2
  publication-title: Gen Dev
  doi: 10.1101/gad.1640608
– volume: 353
  start-page: 1784
  year: 2005
  ident: 2022061106492973200_bib1
  article-title: Effect of screening and adjuvant therapy on mortality from breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa050518
– volume: 39
  start-page: 761
  year: 2010
  ident: 2022061106492973200_bib9
  article-title: Loss of miR-200 inhibition of Suz12 leads to Polycomb-mediated repression required for the formation and maintenance of cancer stem cells
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2010.08.013
– volume: 15
  start-page: 1752
  year: 2008
  ident: 2022061106492973200_bib18
  article-title: Yes-associated protein (YAP) functions as a tumor suppressor in breast
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2008.108
– volume: 369
  start-page: 1742
  year: 2007
  ident: 2022061106492973200_bib2
  article-title: Metastasis: recent discoveries and novel treatment strategies
  publication-title: Lancet
  doi: 10.1016/S0140-6736(07)60781-8
– volume: 9
  start-page: 582
  year: 2008
  ident: 2022061106492973200_bib34
  article-title: A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells
  publication-title: EMBO Rep
  doi: 10.1038/embor.2008.74
– volume: 4
  start-page: e7181
  year: 2009
  ident: 2022061106492973200_bib15
  article-title: miR-200 enhances mouse breast cancer cell colonization to form distant metastases
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0007181
– volume: 37
  start-page: W273
  year: 2009
  ident: 2022061106492973200_bib27
  article-title: DIANA-microT web server: elucidating microRNA functions through target prediction
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkp292
– volume: 2
  start-page: e363
  year: 2004
  ident: 2022061106492973200_bib25
  article-title: Human microRNA targets
  publication-title: PLoS Biol
  doi: 10.1371/journal.pbio.0020363
– volume: 27
  start-page: 431
  year: 2011
  ident: 2022061106492973200_bib29
  article-title: Cytoscape 2.8: new features for data integration and network visualization
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btq675
– volume: 114
  start-page: 457
  year: 2009
  ident: 2022061106492973200_bib40
  article-title: A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2009.05.022
SSID ssj0014104
Score 2.463941
Snippet Purpose: The process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting...
The process of metastases involves the dissociation of cells from the primary tumor, penetration into the basement membrane, invasion, and exiting from the...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 1389
SubjectTerms Adaptor Proteins, Signal Transducing - genetics
Adaptor Proteins, Signal Transducing - metabolism
Animals
Anoikis - genetics
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Cell Movement - genetics
Cell Proliferation
Female
Gene Expression Regulation, Neoplastic
Humans
MCF-7 Cells
Mice
MicroRNAs - genetics
MicroRNAs - metabolism
Neoplasm Metastasis
Phosphoproteins - genetics
Phosphoproteins - metabolism
Transcription Factors
Title MicroRNA-200a Promotes Anoikis Resistance and Metastasis by Targeting YAP1 in Human Breast Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/23340296
https://www.proquest.com/docview/1317850041
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBbtFkovpe-mL1TobXEay5IfxxB2SdMkLUsCyUnIkgyB1ild57D99Z2RZCeBlG57MYmMLDPzMZ73EPIhrniVC60jwIYCA6UwUV4IFtm4xC-MUbHzd8zm6XjJJytxEGh31SVN2de_TtaV_A9XYQ34ilWy_8DZ7qGwAL-Bv3AFDsP1VjyeYTbd1XyIr6sw1QrobrHp8nYDeuE5WNKoHbY1Ad9to-AvdiBBndOlgKOjYD38GqPbw4_rKzFLvcFkMB0Sd9s-Bm0Npb91HtoEde7k9c57mOtocgC5sVudwDnRuv1KushR8FOvNuroxnTnQ0HwiGgWuoIHpwQOiEgiX5bZylEBsov5MRB9e2KtFb7FAcgOJSkGUE-LeJE7bwN2BuYJ649GV5hegk1y9t-0No4__yIvl9OpXFysFnfJPQa2hLO7P33uQk08djMmu7cLZV5wzMeThxwrMH-wSpx2snhEHgazgg49Rh6TO7Z-Qu7PQuLEU6KOoEJbqNAAFbqHCiwZuocKLW9oBxWKUKGbmjqoUA8V6vHwjCwvLxajcRSma0Q6yUQTZWk6YKWIdVZlWaU0Nya3WulU69SUOIUGI-g2qbitWGEKxUSZKaOBHgI0nCx5Ts7qbW1fEmrAKEiUBZYNci4UKwaGpUmiOcgHoVPbI7wlmdSh9TxOQPkmnQkqcomUlkhpCZSWMZNI6R7pd9t--N4rf9vwvuWHBCmJoS9V2-3uWsagJucCm8v1yAvPqO6RLEn4gBXpq1vsfk0e7OH-hpw1P3f2LWilTfnOoeo3DRWGvw
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MicroRNA-200a+promotes+anoikis+resistance+and+metastasis+by+targeting+YAP1+in+human+breast+cancer&rft.jtitle=Clinical+cancer+research&rft.au=Yu%2C+San-Jian&rft.au=Hu%2C+Jing-Ying&rft.au=Kuang%2C+Xia-Ying&rft.au=Luo%2C+Jian-Min&rft.date=2013-03-15&rft.issn=1557-3265&rft.eissn=1557-3265&rft.volume=19&rft.issue=6&rft.spage=1389&rft_id=info:doi/10.1158%2F1078-0432.CCR-12-1959&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon